Document is current
Any future updates will be listed below
-
Authors
Hobson, James J.
Al-khouja, Amer
Curley, Paul
Meyers, David
Flexner, Charles
Siccardi, Marco
Owen, Andrew https://orcid.org/0000-0002-9819-7651
Meyers, Caren Freel
Rannard, Steve P. https://orcid.org/0000-0002-6946-1097
- License Information
-
More Information
Article History
Received: 3 October 2018
Accepted: 1 March 2019
First Online: 29 March 2019
Competing interests
: The authors have also filed patents relating to the FTC prodrugs and their combination with ETFD approaches to form SSPN therapy options. C.F. reports serving as a paid consultant for Cipla Pharmaceuticals, Janssen Pharmaceuticals, Merck Laboratories, Mylan Pharmaceuticals, and ViiV Healthcare, and received research grant support from Gilead Sciences paid to his University. The authors declare no competing interests.
